Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest (

Eli Lilly and Company’s experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer’s disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday.

New Deepfake Spotting Tool Proves 94% Effective – Here’s the Secret of Its Success (

More than HALF of adults who with prior COVID-19 have depression (